Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994746 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
A Phase 3 study of Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 77
- Enrollment target
- 8
- Study locations
NCT01994746 is a Phase 3 study of Diabetes Mellitus, Type 1 that has completed, run by Eli Lilly and Company. The registered enrollment target is 77 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (94% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT01994746, a Phase 3 study of Diabetes Mellitus, Type 1, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 77 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available glucagon given by intramuscular injection.
Conditions Studied
Interventions
- DRUG Nasal Glucagon
- DRUG Intramuscular Glucagon
Study Locations (8)
Colorado
- Barbara Davis Center for Diabetes - Aurora
Connecticut
- Yale University - New Haven
Florida
- University of Florida - Gainesville
Indiana
- Riley Hospital for Children Indiana University Health - Indianapolis
Minnesota
- University of Minnesota - Minneapolis
New York
- UPA Buffalo - Buffalo
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01994746
The ClinicalTrials.gov registry entry for NCT01994746 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (94% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Nasal Glucagon is the first listed.
NCT01994746 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT01994746 about?
NCT01994746 is a clinical study titled "Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults". The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available glucagon given by intramuscular injection.
What is the current status of trial NCT01994746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 77 participants. The study started on 2013-11. Estimated completion is 2015-01.
What conditions does trial NCT01994746 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT01994746?
The interventions under investigation include: Nasal Glucagon (DRUG), Intramuscular Glucagon (DRUG).
Who is sponsoring clinical trial NCT01994746?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01994746 being conducted?
This trial has 8 study locations across Colorado, Connecticut, Florida, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
RECRUITING · Phase 3
-
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
RECRUITING · Phase 3
-
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
RECRUITING · Phase 3
-
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
RECRUITING · Phase 3
-
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.